MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth is a company with a promising future, as its proprietary genomic and molecular tests aim to provide personalized and accurate information for the diagnosis and treatment of cancer. Despite a recent setback with the discontinuation of its Resolve UTI test, the company remains focused on high-growth areas and has a strong internal R&D pipeline. With its expanded sales force and a strong commercial channel, MDxHealth has the potential for low- to mid-teens revenue growth and margin improvement, making it a good investment opportunity.

MDxHealth is facing multiple challenges, with its recent discontinuation of the Resolve UTI test due to a CMS matter, combined with a first quarter miss and lowered guidance for the UTI test. Despite these issues, the acquisition of Exosome Diagnostics from BioTechne adds a key liquid biopsy test to MDxHealth's portfolio and management is confident that sales will rebound and costs will be controlled, although the company's cash flow and balance sheet outlook is tight. We lower our price target from $7 to $4, using a 1.9x multiple on our 2027 revenue estimate of $132M, discounted back 1.5 years. We acknowledge the risks of slower volume growth and reimbursement progress, as well as potential equity dilution.